Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0000929638-25-000790)

Filing Details

Accession Number:: 0000929638-25-000790
Form Type:: 13G Filing
Publication Date:: 2025-02-13 19:00:00

Filed By:: Greenlight Capital
Company:: Coya Therapeutics Inc.
Filing Date:: 2025-02-14
SEC Url:: 13G Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Beneficially Owned Number of Aggregate Shares	Percent of Class
DME Capital Management, LP	1,267,669	7.6%
DME Advisors, LP	383,771	2.3%
DME Advisors GP, L.L.C.	1,651,440	9.9%
EINHORN DAVID	1,651,440	9.9%

Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Coya Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

22407B108

(CUSIP Number)

12/31/2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

22407B108

Names of Reporting Persons

DME Capital Management, LP

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,267,669.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,267,669.00

Aggregate Amount Beneficially Owned by Each Reporting Person

1,267,669.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

7.6 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

22407B108

Names of Reporting Persons

DME Advisors, LP

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 383,771.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 383,771.00

Aggregate Amount Beneficially Owned by Each Reporting Person

383,771.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

2.3 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

22407B108

Names of Reporting Persons

DME Advisors GP, L.L.C.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,651,440.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,651,440.00

Aggregate Amount Beneficially Owned by Each Reporting Person

1,651,440.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

9.9 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

22407B108

Names of Reporting Persons

EINHORN DAVID

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,651,440.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,651,440.00

Aggregate Amount Beneficially Owned by Each Reporting Person

1,651,440.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

9.9 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Coya Therapeutics, Inc.

(b)

Address of issuer's principal executive offices:

5850 San Felipe St., Suite 500, Houston, Texas, 77057

Item 2.

(a)

Name of person filing:

This Amendment No. 2 (the "Amendment") to Schedule 13G relating to common stock, par value $0.0001 per share ("Common Stock") of Coya Therapeutics, Inc., a Delaware corporation (the "Company" or the "Issuer"), as an amendment to the Schedule 13G filed with the SEC on December 12, 2023, as amended on February 14, 2024. This Amendment is being filed on behalf of DME Capital Management, LP, a Delaware limited partnership ("DME CM"), DME Advisors, LP, a Delaware limited partnership ("DME Advisors"), and DME Advisors GP, LLC, a Delaware limited liability company ("DME GP" and together with DME CM and DME Advisors, "Greenlight"), and Mr. David Einhorn, the principal of Greenlight (collectively with Greenlight, the "Reporting Persons"). This Amendment relates to Common Stock of the Issuer held by Greenlight for the account of private investment funds and managed accounts (the "Greenlight Accounts") for which Greenlight acts as investment advisor (or general partner of the investment advisor) and with respect to which Mr. Einhorn may be deemed to have indirect investment and/or voting power as the principal of Greenlight and other affiliated entities. DME GP is the general partner of DME CM and DME Advisors. The filing of this Amendment shall not be construed as an admission that any of the Reporting Persons is for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, the beneficial owner of any of the Common Stock reported herein. Pursuant to Rule 13d-4, each of the Reporting Persons disclaims all such beneficial ownership except to the extent of its pecuniary interest in any shares of Common Stock, if applicable. This Amendment is being filed to amend and restate Item 4.

(b)

Address or principal business office or, if none, residence:

140 East 45th Street, 24th Floor, New York, New York 10017

(c)

Citizenship:

DME CM is a limited partnership organized under the laws of the State of Delaware. DME Advisors is a limited partnership organized under the laws of the State of Delaware. DME GP is a limited liability company organized under the laws of the State of Delaware. David Einhorn is a United States citizen.

(d)

Title of class of securities:

Common Stock, par value $0.0001 per share

(e)

CUSIP No.:

22407B108

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

1,651,440 shares The number of shares of Common Stock reported herein as beneficially owned by the Reporting Persons includes an aggregate of 5,000 shares issuable upon the exercise of warrants. The percentages reported herein are calculated on the basis of the Company's statement in the Company's prospectus dated November 29, 2024 that there were 16,707,441 shares of Common Stock outstanding as of November 4, 2024.

(b)

Percent of class:

9.9 %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

0 shares

(ii) Shared power to vote or to direct the vote:

1,651,440 shares

(iii) Sole power to dispose or to direct the disposition of:

0 shares

(iv) Shared power to dispose or to direct the disposition of:

1,651,440 shares

Item 5.

Ownership of 5 Percent or Less of a Class.

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DME Capital Management, LP

Signature:	/s/ Daniel Roitman
Name/Title:	DME Advisors GP, LLC, its General Partner, by Daniel Roitman/Chief Operating Officer
Date:	02/14/2025

DME Advisors, LP

Signature:	/s/ Daniel Roitman
Name/Title:	DME Advisors GP, LLC, its General Partner, by Daniel Roitman/Chief Operating Officer
Date:	02/14/2025

DME Advisors GP, L.L.C.

Signature:	/s/ Daniel Roitman
Name/Title:	Daniel Roitman/Chief Operating Officer
Date:	02/14/2025

EINHORN DAVID

Signature:	/s/ Daniel Roitman*
Name/Title:	Daniel Roitman, on behalf of David Einhorn
Date:	02/14/2025

Comments accompanying signature: * The Power of Attorney executed by David Einhorn, authorizing the signatory to sign and file Schedule 13G on David Einhorn's behalf, filed as Exhibit 99.1 to the Schedule 13D filed with the Securities and Exchange Commission on August 29, 2019 by the Reporting Persons with respect to the common units of CONSOL Coal Resources, is hereby incorporated by reference.

Exhibit Information

Joint Filing Agreement by and among the Reporting Persons, incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on December 12, 2023.